Credit Suisse’s BioAtla BCAB Stock Holding History

Credit Suisse’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	–	–	4041
2022 Q2	–	Sell	-259	Closed	-$41.2K	–	3932
2022 Q1	$65K	Buy	259 +20	+8%	+$8.37K	﹤0.01%	3503
2021 Q4	$235K	Sell	239 -21	-8%	-$26.9K	﹤0.01%	4217
2021 Q3	$384K	Buy	260 +147	+130%	+$286K	﹤0.01%	3976
2021 Q2	$240K	Buy	+113	New	+$255K	﹤0.01%	4203

Other funds holding BCAB

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Credit Suisse's BCAB Position: Q3 2022 in Review

Credit Suisse held its BioAtla (BCAB) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4041.

Credit Suisse first reported a position in BCAB in Q2 2021 and has held it in 4 quarters since. The position peaked at $384K in Q3 2021. 73 funds tracked by Wall St. Rank hold BCAB as of Q3 2022.

Credit Suisse held 0 shares of BioAtla worth $0 as of Q3 2022.
Credit Suisse left its BioAtla share count unchanged in Q3 2022.
BioAtla made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4041 holding.
Credit Suisse first reported a position in BioAtla in Q2 2021 and has held it in 4 quarters since.
Credit Suisse's BioAtla position peaked at $384K in Q3 2021.
73 funds tracked by Wall St. Rank held BioAtla as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.